S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:MRKR

Marker Therapeutics (MRKR) Stock Price, News & Analysis

$4.14
+0.04 (+0.98%)
(As of 04/19/2024 ET)
Today's Range
$4.05
$4.26
50-Day Range
$3.63
$4.91
52-Week Range
$0.76
$9.68
Volume
14,963 shs
Average Volume
20,900 shs
Market Capitalization
$36.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MRKR stock logo

About Marker Therapeutics Stock (NASDAQ:MRKR)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

MRKR Stock Price History

MRKR Stock News Headlines

Marker Therapeutics Inc (MRKR)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
PSTX, MRKR and GPRO among pre-market losers
Sales Marker Introduces AI Sales to the World
Marker Therapeutics Inc MRKR
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/20/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
67
Year Founded
2018

Profitability

Net Income
$-8,240,000.00
Net Margins
-142.62%
Pretax Margin
-424.10%

Debt

Sales & Book Value

Annual Sales
$3.31 million
Book Value
$1.58 per share

Miscellaneous

Free Float
6,757,000
Market Cap
$36.85 million
Optionable
Not Optionable
Beta
1.50

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Elizabeth Donnelly
    Director of Administration
  • Mr. Edmund Cheung
    Vice President of Human Resources
  • Dr. Nadia Agopyan Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Monic Stuart M.D.
    Chief Medical Officer
  • Mr. Gerald Garrett
    Senior Vice President of Clinical Operations
  • Dr. Robert Z. Florkiewicz Sr.
    Senior Director of Molecular Biology & Virology

MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed in 2024?

Marker Therapeutics' stock was trading at $5.50 at the beginning of 2024. Since then, MRKR shares have decreased by 24.7% and is now trading at $4.14.
View the best growth stocks for 2024 here
.

Are investors shorting Marker Therapeutics?

Marker Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 107,900 shares, a decrease of 27.9% from the March 15th total of 149,700 shares. Based on an average daily volume of 21,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 1.7% of the company's stock are short sold.
View Marker Therapeutics' Short Interest
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. Marker Therapeutics had a negative net margin of 142.62% and a negative trailing twelve-month return on equity of 39.89%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRKR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners